Compare Sanofi SA (SNY) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Target Corporation — how do they compare? Sanofi SA trades at $43.12 (market cap $103.41B), while Target Corporation trades at $158.01 (market cap $71.56B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| SNY | TGT | |
|---|---|---|
Market Cap | $103.41B | $71.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $169.90 |
52-Week Low | $41.33 | $83.68 |
Enterprise Value | $123.44B | $84.84B |
Dividend Yield | 5.65% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Target (TGT) trades at $162.71, down 1.05% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly EPS beats. Revenue remains stable near $107B, while valuation ratios like P/E of 16.88 and P/S of 0.69 suggest reasonable pricing. Recent news highlights CEO Michael Fiddelke's turnaround success, with shares surging over 70% year-to-date.
Outlook is positive with analyst consensus at $166.67 and 47% buy ratings, but risks include competitive retail pressures and margin compression. The dividend yield of approximately 2.85% adds income appeal, though valuation expansion from recent gains warrants caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
